Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer
出版年份 2016 全文链接
标题
Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer
作者
关键词
Meta-analysis as topic, Systematic reviews, Randomized controlled trials, Network meta-analysis, Non-small cell lung cancer
出版物
BMC Medicine
Volume 14, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-01-20
DOI
10.1186/s12916-016-0555-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review
- (2016) Alexandra Brazinova et al. JOURNAL OF NEUROTRAUMA
- A New Approach to Evidence Synthesis in Traumatic Brain Injury: A Living Systematic Review
- (2016) Anneliese Synnot et al. JOURNAL OF NEUROTRAUMA
- Adherence to Guidelines in Adult Patients with Traumatic Brain Injury: A Living Systematic Review
- (2016) Maryse C. Cnossen et al. JOURNAL OF NEUROTRAUMA
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?
- (2015) Huseyin Naci et al. Annual Review of Pharmacology and Toxicology
- Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
- (2015) Bing-Kun Xiao et al. Asian Pacific Journal of Cancer Prevention
- Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination
- (2015) Bartosz Helfer et al. BMC Medicine
- Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
- (2015) Claire L. Vale et al. Clinical Lung Cancer
- Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis
- (2015) Sanjay Popat et al. Future Oncology
- Automating Risk of Bias Assessment for Clinical Trials
- (2015) Iain J Marshall et al. IEEE Journal of Biomedical and Health Informatics
- A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants
- (2015) Robert G. Badgett et al. JAMA Pediatrics
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- A Living Meta-analysis of Colchicine for Pericarditis
- (2014) Patrick Ters et al. ANNALS OF PHARMACOTHERAPY
- Using conditional power of network meta-analysis (NMA) to inform the design of future clinical trials
- (2014) Adriani Nikolakopoulou et al. BIOMETRICAL JOURNAL
- Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC who Failed First-Line Treatment
- (2014) Ying Jin et al. CLINICAL THERAPEUTICS
- Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials
- (2014) Xuyuan Li et al. CURRENT MEDICAL RESEARCH AND OPINION
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reducing systematic review workload through certainty-based screening
- (2014) Makoto Miwa et al. JOURNAL OF BIOMEDICAL INFORMATICS
- How to increase value and reduce waste when research priorities are set
- (2014) Iain Chalmers et al. LANCET
- Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
- (2014) Ning Zhao et al. LUNG CANCER
- A Bayesian Mixed-Treatment Comparison Meta-analysis of Treatments for Alcohol Dependence and Implications for Planning Future Trials
- (2014) Stacia M. DeSantis et al. MEDICAL DECISION MAKING
- Using Crowdsourcing to Evaluate Published Scientific Literature: Methods and Example
- (2014) Andrew W. Brown et al. PLoS One
- Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
- (2014) Ning Li et al. PLoS One
- Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
- (2014) Wenhua Liang et al. PLoS One
- The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review
- (2014) XiongWen Yang et al. Current Oncology Reports
- Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer
- (2014) Maria Antonia Pérez-Moreno et al. International Journal of Clinical Pharmacy
- A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
- (2014) M. A. Puhan et al. BMJ-British Medical Journal
- Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial
- (2014) A. Maruani et al. BMJ-British Medical Journal
- Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap
- (2014) Julian H. Elliott et al. PLOS MEDICINE
- Exploring the Geometry of Treatment Networks
- (2013) Georgia Salanti et al. ANNALS OF INTERNAL MEDICINE
- Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
- (2013) Wei-Xiang Qi et al. Asian Pacific Journal of Cancer Prevention
- From ClinicalTrials.gov trial registry to an analysis-ready database of clinical trial results
- (2013) M Soledad Cepeda et al. Clinical Trials
- Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses
- (2013) Huseyin Naci et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents
- (2013) Anna-Bettina Haidich et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Evidence Synthesis for Decision Making 1
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
- (2013) Wei-Xiang Qi et al. PLoS One
- The Geometric Increase in Meta-Analyses from China in the Genomic Era
- (2013) John P. A. Ioannidis et al. PLoS One
- The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials
- (2013) Jianlan Cui et al. PLoS One
- The automation of systematic reviews
- (2013) G. Tsafnat et al. BMJ-British Medical Journal
- Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review
- (2013) A. Bafeta et al. BMJ-British Medical Journal
- Overlapping meta-analyses on the same topic: survey of published studies
- (2013) K. C. Siontis et al. BMJ-British Medical Journal
- The effects of excluding treatments from network meta-analyses: survey
- (2013) E. J. Mills et al. BMJ-British Medical Journal
- Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty
- (2012) Asba Tasneem et al. PLoS One
- Tocolytic therapy for preterm delivery: systematic review and network meta-analysis
- (2012) D. M. Haas et al. BMJ-British Medical Journal
- Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer
- (2011) Davide Tassinari et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer
- (2011) Wei-Xiang Qi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Need to realign patient-oriented and commercial and academic research
- (2011) Alessandro Liberati LANCET
- The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials
- (2011) Wei-Xiang Qi et al. LUNG
- Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
- (2010) Jingwei Jiang et al. ACTA ONCOLOGICA
- Semi-automated screening of biomedical citations for systematic reviews
- (2010) Byron C Wallace et al. BMC BIOINFORMATICS
- Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?
- (2010) Hilda Bastian et al. PLOS MEDICINE
- Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses
- (2009) J. P.A. Ioannidis CANADIAN MEDICAL ASSOCIATION JOURNAL
- Second-Line Treatments in Non-small Cell Lung Cancer
- (2009) Davide Tassinari et al. CHEST
- AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews
- (2009) Beverley J. Shea et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data
- (2009) Neil Hawkins et al. VALUE IN HEALTH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started